CAVA's EBITDA Lags Revenue Growth Amid Cost Pressures, Confirming Margin Risks

What happened

CAVA's revenue growth continues to outpace EBITDA, as highlighted in a recent Zacks article, due to expansion spending and rising operating costs squeezing margins. This aligns with the DeepValue report's findings, which show same-restaurant sales decelerating sharply from 13.4% in 2024 to 1.9% in Q3 2025, with flat traffic and restaurant-level margins compressing to 24.6%. Management has cut guidance and avoids heavy discounting, but inflationary pressures on food, labor, and tariffs are limiting profitability flow-through. At a high valuation of around 57x trailing EPS, the market assumes a recovery in comps and margins that may be at risk if these trends persist. Investors are now weighing whether this is a temporary investment phase or a signal of deeper margin erosion in a competitive, value-sensitive environment.

Implication

The lag in EBITDA growth relative to revenue underscores that CAVA's aggressive expansion is costly and may not deliver immediate returns, pressuring near-term earnings and cash flow. With same-restaurant sales slowing and margins under siege, the company's ability to justify high valuation multiples is increasingly questionable, heightening downside risk. Management's reluctance to engage in heavy discounting reflects brand confidence but limits short-term traffic boosts, potentially extending the sales slump in a tough macro backdrop. Investors must closely monitor upcoming FY26 guidance for same-restaurant sales and margins, as any further deterioration could validate bearish scenarios and trigger additional stock declines. Ultimately, success depends on CAVA leveraging technology and loyalty to drive efficiency without sacrificing growth, but current data favors a defensive stance or trimming exposure until trends stabilize.

Thesis delta

The new article reinforces the DeepValue report's cautious stance by explicitly noting that EBITDA growth is lagging revenue, highlighting persistent margin risks from expansion and inflation. This does not alter the core thesis but strengthens the argument for reducing exposure until clear evidence of margin stabilization and comp re-acceleration emerges. Investors should view any price rallies above $80 with skepticism and consider waiting for a more attractive entry near $55 to mitigate downside from potential further disappointments.